It's small wonder that start-up activity and collaboration around treatments for irritable bowel syndrome (IBS) are as spasmodic as the condition they seek to alleviate. The disease is a conundrum, with multiple biological triggers causing opposing symptoms in patients. Only in the last 10-15 years has the medical community agreed upon symptom-based diagnostic criteria for IBS.
IBS affects 85 million people in the US and top European markets. Of those, approximately five million are now treated...
Welcome to Scrip
Create an account to read this article
Already a subscriber?